If EPS Growth Is Important To You, Concurrent Technologies (LON:CNC) Presents An Opportunity
Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Concurrent Technologies (LON:CNC). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Concurrent Technologies with the means to add long-term value to shareholders.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Concurrent Technologies' Earnings Per Share Are Growing
If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. That makes EPS growth an attractive quality for any company. We can see that in the last three years Concurrent Technologies grew its EPS by 12% per year. That's a pretty good rate, if the company can sustain it.
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. EBIT margins for Concurrent Technologies remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 27% to UK£40m. That's a real positive.
The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.
Check out our latest analysis for Concurrent Technologies
The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Concurrent Technologies' future EPS 100% free.
Are Concurrent Technologies Insiders Aligned With All Shareholders?
It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. So it is good to see that Concurrent Technologies insiders have a significant amount of capital invested in the stock. Indeed, they hold UK£14m worth of its stock. This considerable investment should help drive long-term value in the business. As a percentage, this totals to 9.3% of the shares on issue for the business, an appreciable amount considering the market cap.
Does Concurrent Technologies Deserve A Spot On Your Watchlist?
One positive for Concurrent Technologies is that it is growing EPS. That's nice to see. If that's not enough on its own, there is also the rather notable levels of insider ownership. That combination is very appealing. So yes, we do think the stock is worth keeping an eye on. If you think Concurrent Technologies might suit your style as an investor, you could go straight to its annual report, or you could first check our discounted cash flow (DCF) valuation for the company.
There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of British companies which have demonstrated growth backed by significant insider holdings.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Enigmatig Celebrates NYSE American Listing with Bell Ringing Ceremony, Signaling Next Phase of Global Growth
NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Enigmatig Limited (NYSE American: EGG) ("Enigmatig" or the "Company"), a global business enabler empowering small and medium-sized enterprises (SMEs) to scale across borders, today rang the Closing Bell at the New York Stock Exchange ("NYSE") to mark its recent listing and reaffirm its mission to power the global ambitions of bold, forward-thinking businesses. Enigmatig began trading on June 18, 2025, following the completion of its initial public offering of 3,005,200 Class A ordinary shares at US$5.00 per share including the partial exercise of the underwriters' overallotment option. The offering raised gross proceeds of approximately US$15 million. Prime Number Capital LLC acted as the sole book-running manager for the offering. As one of the few Asia-Pacific headquartered firms in its sector to list on the NYSE American, this accomplishment underscores Enigmatig's role as a trusted partner for SMEs navigating high-stakes cross-border expansion, regulatory complexities, and new market entries. Desmond Foo, Founder and CEO of Enigmatig, said, "Today's bell ringing is a proud milestone in our 15-year journey of enabling SMEs to achieve their international ambitions. Our listing strengthens our foundation for bold, global expansion, enabling us to deepen our service capabilities, advance our RegTech innovations, and extend our reach across the world's key financial hubs. Enigmatig was built to guide clients throughout their expansion journey – from incorporation to licensing, compliance, and strategic growth – delivering clarity, precision, and partnership every step of the way." Mingwen Teo, the Company's Director and CFO, added, "Our successful IPO and strong first-half performance validate the strength of our business model and the growing demand for comprehensive, technology-enabled licensing and compliance solutions. This ceremony is not just a celebration of our listing, but also a reaffirmation of our long-term vision to empower compliance globally while creating sustainable value for our clients and shareholders." With its IPO proceeds, Enigmatig is driving its next wave of growth by: Expanding its leadership and specialist teams across key markets and verticals Accelerating RegTech and automation innovation to streamline compliance Enhancing strategic advisory with sharper, data-driven insights Pursuing targeted M&A to strengthen its global service offerings Growing its presence in high-potential markets to serve clients closer to where they operate and aspire to operate Founded in 2010, Enigmatig has built a strong track record across global financial hubs and offshore jurisdictions, including Singapore, Hong Kong, Shanghai, London, Cyprus, and Belize, delivering tailored solutions across the full business lifecycle, from company incorporation to ongoing compliance and strategic advisory. Its proprietary CRM platform, integrating KYC, AML, and transaction monitoring tools, positions RegTech at the core of the Company's growth strategy, allowing smarter, faster compliance for both new and existing clients. For photos, a video replay and other content from the event, please visit: About Enigmatig Limited Enigmatig is an international business enabler dedicated to helping small and medium-sized enterprises (SMEs) achieve their international ambitions. Since 2010, we have connected businesses with the expertise, infrastructure, and regulatory support needed to succeed in cross-border markets. With deep capabilities in FX brokerage consultancy, licensing, RegTech, FinTech, and corporate services, Enigmatig delivers tailored solutions across the full business lifecycle – from company incorporation to ongoing compliance. Our experienced team specializes in navigating complex regulatory environments across global financial hubs and key offshore centers, including London, Cyprus, and Belize. Headquartered in Singapore with a strategic presence in Hong Kong, Shanghai, London, and a representative desk in Bangkok, Enigmatig supports a diverse and growing international client base. For more information, please visit: Safe Harbor Statement Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "could," "will," "should," "would," "expect," "plan," "aim," "intend," "anticipate," "believe," "estimate," "predict," "is/are likely to," "potential," "project" or "continue" or the negative of these terms or other comparable or similar terminology. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC, which are available for review at Media & Investor Contacts: investors@ View original content to download multimedia: SOURCE Enigmatig
Yahoo
2 hours ago
- Yahoo
AmpliTech Group Inc (AMPG) Q2 2025 Earnings Call Highlights: Record Sales and Strategic ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AmpliTech Group Inc (NASDAQ:AMPG) achieved record sales of over $11 million in Q2 2025, surpassing total sales for the entire 2024 fiscal year. The company has a strong financial position with $16,423,000 in cash and cash equivalents and no long-term debt. AmpliTech Group Inc (NASDAQ:AMPG) has secured multiple purchase orders and LOIs with prominent 5G players, indicating strong future revenue potential. The company is strategically positioned to benefit from major US government initiatives, including rural broadband funding and the CHIPS Act. AmpliTech Group Inc (NASDAQ:AMPG) is the only US-based company providing complete vertically integrated end-to-end commercial and defense-grade networking solutions, offering a trusted alternative to foreign suppliers. Negative Points The company experienced lower than normal gross profit margins in Q2 2025 due to front-loaded investments and one-time costs. AmpliTech Group Inc (NASDAQ:AMPG) incurred several one-time costs, including license fees and initial production line fees, which impacted profitability. The quantum computing business is not yet at a production phase, limiting immediate revenue potential from this segment. The satellite business is expected to start generating revenue only next year, indicating a delay in realizing returns from this division. The company had to expedite material and pay premiums to meet Q2 delivery requirements, which increased costs and affected margins. Q & A Highlights Warning! GuruFocus has detected 4 Warning Signs with AMPG. Q: Can you provide more details on the orders from the second tier one customer and the expected timeline for additional orders? A: We have already received orders from the second tier one customer, which are part of our backlog. We have two main Letters of Intent (LOIs), one for $170 million and another for $40 million. We have actively shipped against the $40 million LOI during Q2 and received additional orders for production quantities for this year and the start of next year. For the $170 million LOI, we have received about $2.5 million worth of orders, with the bulk expected between 2026 and 2027. George Flores, COO Q: How is the pipeline looking with other operators around the world? A: While we can't provide specific numbers, the transition to 5G OAN technology is imminent for many other MNOs. Our successful implementation with current partners has made it more viable for other large MNOs to pursue this opportunity. We expect a positive response from other MNOs next year. Pava McGul, CEO Q: Can you update us on the progress in the quantum computing space? A: Quantum computing is not yet at a production phase. We have delivered products to large companies, but the market is still in R&D. Quantum computing will eventually power AI, replacing current silicon applications. When production ramps up, our components will be essential, but this is not expected immediately. Pava McGul, CEO Q: What is the status of your space division and the backlog for next year? A: Our space products are geared towards low Earth orbit applications. The satellite business is expected to start next year as satellites are being built out. We have developed space-qualified hardware to support these applications, but significant demand is anticipated to begin next year. Pava McGul, CEO Q: How are you managing inventory and manufacturing to meet demand? A: We have a strong relationship with our customers, allowing us to see their forecasts and activate our supply chain accordingly. This has helped us avoid expediting costs and manage inventory effectively. We are building to order and keeping inventory levels manageable to support upcoming orders across our divisions. George Flores, COO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
2 hours ago
- Yahoo
Asian Market Insights: CNMC Goldmine Holdings And 2 Other Noteworthy Penny Stocks
As global markets respond to economic data and rate cut speculations, Asian indices have shown resilience amid these shifting dynamics. In this context, penny stocks—often representing smaller or newer companies—remain a relevant investment area despite their somewhat outdated label. By focusing on those with robust financials, investors can uncover potential opportunities for growth; here we examine CNMC Goldmine Holdings and two other noteworthy examples that may offer both stability and upside in the evolving market landscape. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.06 THB4.01B ★★★★★☆ Lever Style (SEHK:1346) HK$1.47 HK$909.23M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.49 HK$2.07B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.645 SGD261.41M ★★★★★☆ China Sunsine Chemical Holdings (SGX:QES) SGD0.69 SGD657.83M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.91 SGD11.45B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.96 THB1.41B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Rojana Industrial Park (SET:ROJNA) THB4.76 THB9.62B ★★★★★★ BRC Asia (SGX:BEC) SGD3.50 SGD960.23M ★★★★★★ Click here to see the full list of 972 stocks from our Asian Penny Stocks screener. Let's uncover some gems from our specialized screener. CNMC Goldmine Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: CNMC Goldmine Holdings Limited is an investment holding company focused on the exploration and mining of gold deposits in Malaysia, with a market cap of SGD261.41 million. Operations: The company generates revenue primarily from its mining operations, totaling $88.33 million. Market Cap: SGD261.41M CNMC Goldmine Holdings has demonstrated robust financial performance, with earnings growing by 210.3% over the past year, significantly outpacing the industry. The company reported a net income of US$15.76 million for H1 2025, up from US$4.43 million the previous year, reflecting strong operational efficiency and high-quality earnings. Its short-term assets (US$51.3M) comfortably cover both short- and long-term liabilities, indicating solid financial health. Despite significant insider selling recently and an unstable dividend track record, CNMC's seasoned management team and favorable valuation compared to peers suggest potential for continued growth in this volatile sector. Click here to discover the nuances of CNMC Goldmine Holdings with our detailed analytical financial health report. Gain insights into CNMC Goldmine Holdings' future direction by reviewing our growth report. LifeTech Scientific Simply Wall St Financial Health Rating: ★★★★★★ Overview: LifeTech Scientific Corporation is an investment holding company that develops, manufactures, and trades interventional medical devices for cardiovascular and peripheral vascular diseases across Mainland China and other international markets, with a market cap of approximately HK$10.04 billion. Operations: The company's revenue is derived from three main segments: Structural Heart Diseases Business generating CN¥527.58 million, Peripheral Vascular Diseases Business contributing CN¥751.11 million, and Cardiac Pacing and Electrophysiology Business with CN¥25.01 million. Market Cap: HK$10B LifeTech Scientific Corporation, with a market cap of approximately HK$10.04 billion, operates debt-free and demonstrates financial stability by covering its short- and long-term liabilities with CN¥2.3 billion in short-term assets. However, the company faces challenges with negative earnings growth over the past year despite a 7.9% annual profit increase over five years. Its net profit margin has declined to 17.1% from 20.8%, reflecting pressures on profitability, while Return on Equity remains low at 4.8%. Recent board appointments may strengthen governance as LifeTech navigates industry competition amid stable volatility levels in its stock performance. Navigate through the intricacies of LifeTech Scientific with our comprehensive balance sheet health report here. Examine LifeTech Scientific's past performance report to understand how it has performed in prior years. SSY Group Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: SSY Group Limited is an investment holding company that engages in the research, development, manufacturing, trading, and sale of pharmaceutical products to hospitals and distributors both within the People's Republic of China and internationally, with a market cap of HK$9.06 billion. Operations: The company's revenue is primarily generated from its Intravenous Infusion Solution and Others segment, which accounts for HK$5.59 billion, followed by the Medical Materials segment with HK$405.07 million. Market Cap: HK$9.06B SSY Group Limited, with a market cap of HK$9.06 billion, primarily generates revenue from its Intravenous Infusion Solution segment. Recent approvals by China's National Medical Products Administration for drugs like Fampridine and Drotaverine Hydrochloride highlight the company's active pharmaceutical development strategy. Despite this, SSY faces challenges with negative earnings growth over the past year and a declining net profit margin to 18.4%. The company's financials show stability with short-term assets covering both short- and long-term liabilities, while interest payments are well covered by EBIT. However, dividend sustainability remains a concern due to limited free cash flow coverage. Take a closer look at SSY Group's potential here in our financial health report. Review our growth performance report to gain insights into SSY Group's future. Make It Happen Click this link to deep-dive into the 972 companies within our Asian Penny Stocks screener. Curious About Other Options? Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include Catalist:5TP SEHK:1302 and SEHK:2005. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
